Date: 2014-04-07
Type of information: Grant
Company: Absolute Antibody (UK)
Investors: Technology Strategy Board (UK) and business angels
Amount: £850K ($1.4M - €1.02 million)
Funding type: grant
Planned used: The investment will be used to accelerate the growth of the business by building up Absolute Antibody\'s library of engineered antibodies and manufacturing capacity. The Company has also announced the commercial launch of its suite of recombinant antibody services and catalogue of engineered antibody products, initially targeted at the research antibody market.
Absolute Antibody has developed a proprietary manufacturing platform based on transient transfection for the production of sequenced and engineered antibodies, AbsoluteAbs (AbAbs). These engineered antibodies provide a number of benefits over antibodies produced using traditional methods, including ultra-low batch-to-batch variability leading to improved reproducibility of results, and the ability to eliminate undesirable properties or add desirable features.
Others: * On April 7, 2014, Absolute Antibody, a life sciences company developing next generation engineered antibodies for biomedical research and diagnostics markets, has announced that it has received £850K ($1.4 million - €1.02 million) funding. The investment includes a £100K Smart proof of concept funding award from the Technology Strategy Board and £750K from the founders and a group of business angels.
Therapeutic area:
